Achieving optimal lipid management with evolocumab (Repatha) in high-risk ASCVD patients

Sponsored by Amgen Australia Pty Ltd

With an expanded eligibility criteria announced earlier this year, evolocumab (Repatha) can now be prescribed for patients with or without familial hypercholesterolaemia (FH). To be eligible for treatment non-FH patients must have symptomatic atherosclerotic cardiovascular disease (ASCVD) and at least one additional risk factor and must have been optimally treated for more than 12 weeks ...

Already a member?

Login to keep reading.

© 2021 the limbic